长期和低剂量rituximab治疗慢性炎症性脱髓化多神经病变
Yongsheng Zheng1,2,3, Chong Sun1,2,3, Yanyin Zhao1,2,3
1Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Journal of the peripheral nervous system : JPNS
|August 17, 2024
概括
低剂量,长期的rituximab治疗对异形性慢性炎症性脱髓化多神经病 (CIDP) 有希望. 这种疗法在CIDP患者中显示出显著的临床改善和有利的安全概况.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常性CIDP是一种罕见的自身免疫性疾病,影响周围神经.
- 目前对CIDP的治疗方法可能会产生显著的副作用或有限的疗效.
- 需要安全有效的长期治疗方案来治疗CIDP.
研究的目的:
- 为了评估低剂量,长期的rituximab治疗方案的疗效和安全性,用于特异性CIDP.
- 为了评估接受Rituximab的CIDP患者的临床改善和治疗耐受性.
- 为了确定rituximab是否可以减少对其他CIDP药物的需求.
主要方法:
- 一项涉及15名患有异常性CIDP的患者的研究.
- 患者每六个月内静脉注射600毫克瑞图西马布.
- 临床评估是在治疗前和每次输液后六个月使用标准化量表 (INCAT,mRS,MRC,cI-RODS) 进行的.
主要成果:
- 60%的患者在第一次Rituximab输注后显示出显著的临床改善.
- 在73%的患者中,rituximab治疗导致减少或停止使用其他药物.
- 安全性概况有利,在研究期间没有报告任何不良事件.
结论:
- 低剂量,长期的rituximab疗法是一种潜在的有效和安全的治疗特异性CIDP.
- 利图西马布提供了一个有前途的治疗策略,用于管理CIDP,具有良好的耐受性.
- 进一步的研究可能会支持Rituximab作为CIDP的标准治疗选择.
更多相关视频
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.2K
03:53Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
Published on: March 15, 2024
1.5K
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...